Sunrest Lifescience logo

Sunrest Lifescience financials and balance sheet

NSE: SUNRESTPharmaceuticals & Biotechnology

Last close ₹33.50down ₹1.50 (4.29%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹35.00.

52-week range of traded prices to 23 Oct 2026
₹29.55Low, 21 Jan 2026₹54.00High, 25 Nov 2025
Market cap
₹29 Cr
P/E
7.0
P/B
Shares changed
Dividend yield
Nonein the last 12 months
ROE
22.4%
Debt to equity
0.59
Volume, NSE
4,800

3 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Sunrest Lifescience annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹33 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue33
  2. Materials and goods−17
  3. Employee costs−5.7
  4. Other expenses−5.8
  5. Operating profit4.8
  6. Depreciation−0.2
  7. Other income0.0
  8. Finance costs−0.5
  9. Profit before tax4.1
  10. Tax−1.0
  11. Net profit3.1

What the company owns

  • Receivables₹19 Cr
  • Plant, investments and other assets₹11 Cr
  • Inventory₹11 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹19 Cr
  • Owed to suppliers₹11 Cr
  • Borrowings₹9 Cr
  • Other liabilities₹2 Cr

Profit and loss

Standalone, ₹ crore, years to March.Sunrest Lifescience half-yearly results

₹ croreMar 2024Mar 2025Filed 30 MayMar 2026Filed 29 May
Revenue from operations29.533.133.3
28.630.128.4
Materials and goods bought20.019.816.9
Employee costs3.84.95.7
Other expenses4.85.45.8
Operating profit before depreciation0.93.04.8
Operating margin3.1%9.1%14.5%
Materials, % of revenue67.8%59.9%50.9%
Employee costs, % of revenue13.0%14.6%17.2%
Other expenses, % of revenue16.1%16.4%17.5%
Depreciation and amortisation0.10.10.2
Operating profit after depreciation0.82.94.6
Other income0.00.00.0
Finance costs0.20.30.5
One-off items0.0––
Profit before tax0.62.64.1
0.40.61.0
Net profit0.22.03.1
Net margin0.8%6.0%9.3%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2025Filed 30 MayMar 2026Filed 29 May
16.219.3
Share capital4.34.3
Reserves11.915.0
6.29.2
14.514.2
4.47.9
Total assets35.241.4
6.98.2
28.333.1
Net debt5.98.7
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2025Filed 30 MayMar 2026Filed 29 May
1.43−0.68
1.91−0.63
−1.09−4.95
Receivables−4.010.40
Inventories−1.73−4.11
Payables7.61−0.41
Other working capital−2.96−0.83
Tax paid−0.48−0.56
Interest paid0.000.51
Capital spending1.361.58
Free cash flow0.06−2.26
−1.14−1.58
−0.302.49
Dividends paid0.000.00
Shares issued0.000.00
Net change in cash−0.010.23
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the year to Mar 2024.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2024Mar 2025Filed 30 MayMar 2026Filed 29 May
Earnings per share–₹4.66₹7.20
Diluted earnings per share–₹4.66₹7.20
Book value per share–₹37.72₹44.91
Shareholder yield–0.0%0.0%
Market cap at the year end (₹ crore)26.223.115.9

Ratios

Standalone, years to March.Sunrest Lifescience PE ratio and valuation

RatioMar 2024Mar 2025Filed 30 MayMar 2026Filed 29 May
Revenue growth–12.3%0.4%
Operating profit growth–230.6%60.7%
Net profit growth–786.1%54.4%
Earnings per share growth––54.5%
–12.4%17.4%
––5.1 pts
From the net margin––6.6 pts
From asset turnover––−1.5 pts
From borrowing––−0.1 pts
Return on capital employed–13.0%16.1%
Cash conversion–71.3%−22.0%
Interest cover3.79.69.0
Debt to equity–0.380.48
Receivable days–209204
Inventory days–125235
Payable days–210237
Cash conversion cycle, days–125202
Working capital days–171220
Asset turnover–0.940.87
Assets per rupee of net worth–2.172.16
Sales per rupee of plant–25.1212.47
Capital spending to depreciation–15.136.76
No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.1%
Cash from operations against operating profit
−14.1%
Measure3 years
Return on equity, average14.9%
Return on capital employed, average14.6%
Operating margin, average8.9%
Net margin, average5.4%
Asset turnover, average0.91
Cash conversion cycle, days, average163
Interest cover, average7.4
Debt to equity, average0.43

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations−0.68
Cash from investing−1.58
Cash from financing2.49
Capital spending1.58
Dividends paid0.00
Shares issued for cash0.00
Borrowings raised3.01
Borrowings repaid0.00

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2024Mar 2025Mar 2026
Effective tax ratePublished threshold 17.16 per cent61.92––
A threshold marked as ours has no published figure; it is the line we read the check against.